



1073

FORM P-1449	SERIAL NO. 10743,281	CASE NO. 10709/63
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE December 22, 2003	GROUP ART UNIT 1616
(use several sheets if necessary)		APPLICANT(S): Melikian A., et al.

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A1	4,166,452	09/04/1979	Generales, Jr.		
	A2	4,256,108	03/17/1981	Theeuwes		
	A3	4,265,874	05/05/1981	Bonsen et al.		
	A4	4,927,838	05/22/1990	Guthrie et al.		
	A5	5,994,519	11/30/1999	Osourn et al.		
	A6	6,084,075	04/04/2000	Lind et al.		
	A7	6,140,064	10/31/2000	Loetscher et al.		
SLB	A8	6,156,520	12/05/2000	Inglese et al.		
	A9	6,180,336 B1	01/30/2001	Osourn et al.		
	A10	6,184,358 B1	02/06/2001	Loetscher et al.		
	A11	6,329,159 B1	12/11/2001	Andrew et al.		
	A12	6,365,356 B1	04/02/2002	Gershengorn		
	A13	6,448,054 B1	09/10/2002	Poznansky et al.		
	A14	US 2002/0004215 A1	01/10/2002	Osourn et al.		
	A15	US 2002/0025536 A1	02/28/2002	Gyuris et al.		
	A16	US 2002/0034757 A1	03/21/2002	Cubiccioni		
	A17	US 2002/0037539 A1	03/28/2002	Qin et al.		
	A18	US 2002/0048786 A1	04/25/2002	Rosen et al.		
	A19	US 2002/0061599 A1	05/23/2002	Elling et al.		
	A20	US 2002/0061834 A1	05/23/2002	Rosen et al.		
	A21	US 2002/0064770 A1	05/30/2002	Nestor, Jr. et al.		
	A22	US 2002/0076710 A1	06/20/2002	Papsidero et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES OR NO
SLB	A23	EP 0 897 980 A2	02/24/1999	EPO		Yes
	A24	WO 98/11218	03/19/1998	WIPO		Yes
	A25	WO 98/14480	04/09/1998	WIPO		Yes
	A26	WO 99/50461	10/07/1999	WIPO		Yes

EXAMINER INITIAL	OTHER ART - NON PATENT LITERATURE DOCUMENTS <small>(Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.</small>	
SLB	A27	Abdel-Magid et al., "Reductive Amination of Aldehydes and Ketones by Using Sodium Triacetoxyborohydride," <i>Tetrahedron Lett.</i> , 31:5595-5598 (1990).
EXAMINER	SABHA QAZI	DATE CONSIDERED 8/25/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	SERIAL NO. 10/743,281	CASE NO. 10709/63
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE December 22, 2003	GROUP ART UNIT 1616
(use several sheets if necessary)		APPLICANT(S): Melikian A., et al.

EXAMINER INITIAL	OTHER ART – NON PATENT LITERATURE DOCUMENTS (Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.	
	A28	Babcock et al., "Ligand Binding Characteristics of CXCR4 Incorporated into Paramagnetic Proteoliposomes," <i>J. Biol. Chem.</i> , 276(42):38433-38440 (2001).
	A29	Baribaud et al., "Antigenically Distinct Conformations of CXCR4," <i>J. Virol.</i> , 75(19):8957-8967 (2001).
	A30	Barney et al., "A Convenient Synthesis of Hindered Amines and α -Trifluoromethylamines from Ketones," <i>Tetrahedron Lett.</i> , 31:5547 (1990).
	A31	Bertolini et al., "Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma," <i>Blood</i> , 1(96):282-287 (2000).
	A32	Bertolini et al., "CXCR4 Neutralization, a Novel Therapeutic Approach for Non-Hodgkin's Lymphoma ¹ ," <i>Cancer Research</i> , 62:3106-3112 (2002).
	A33	Dairaghi et al., "HHV8-encoded vMIP-I Selectively Engages Chemokine Receptor CCR8," <i>J. Biol. Chem.</i> , 274(31):21569-21574 (1999).
	A34	Tatjana Dragic, "An overview of the determinants of CCR5 and CXCR4 co-receptor function," <i>J. Gen. Virol.</i> , 82:1807-1814 (2001).
SL	A35	Förster et al., "Intracellular and Surface Expression of the HIV-1 Coreceptor CXCR4/Fusin on Various Leukocyte Subsets: Rapid Internalization and Recycling Upon Activation," <i>J. Immunol.</i> , 160:1522-1531 (1998).
	A36	Gerlach et al., "Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor," <i>J. Biol. Chem.</i> , 276(17):14153-14160 (2001).
	A37	Gosling et al., "Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell- and T Cell-Active Chemokines Including ELC, SLC, and TECK," <i>J. Immunol.</i> , 164(6):2851-2856 (2000).
	A38	Gribble GW and Nutaitis CF, "Reactions of Sodium Borohydride in Acidic Media; XVI. N-Methylation of Amines with Paraformaldehyde/Trifluoroacetic Acid," <i>Synthesis</i> , 709 (1987).
	A39	Kevill DN and Rissmann TJ, "Correlation of the Rates of Solvolysis of Allyl and Benzyl Arenesulphonates," <i>J. Chem. Soc. Perkin Trans. 2</i> :717-720 (1984)
	A40	Kledal et al., "A Broad-Spectrum Chemokine Antagonist Encoded by Kaposi's Sarcoma-Associated Herpesvirus," <i>Science</i> , 277:1656-1659 (1997).
	A41	Lee et al., "Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function," <i>J. Biol. Chem.</i> , 274(14):9617-9626 (1999).
	A42	Lin et al., "Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2," <i>Proc. Natl. Acad. Sci. USA</i> , 95:8829-8834 (1998).
	A43	Lance A. Liotta, "An attractive force in metastasis," <i>Nature</i> , 410:24-25 (2001).
	A44	Mattson et al., "An Improved Method for Reductive Alkylation of Amines Using Titanium (IV) Isopropoxide and Sodium Cyanoborohydride ¹ ," <i>J. Org. Chem.</i> , 55:2552-2554 (1990).
	A45	Moepps et al., "Two murine homologues of the human chemokine receptor CXCR4 mediating stromal cell-derived factor 1 α activation of G ₁₂ are differently expressed <i>in vivo</i> ," <i>Eur. J. Immunol.</i> , 27:2102-2112 (1997).

EXAMINER SABINA GAZI	DATE CONSIDERED 8/25/07
-------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	SERIAL NO. 10/743,281	CASE NO. 10709/63
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE December 22, 2003	GROUP ART UNIT 1616
(use several sheets if necessary)		APPLICANT(S): Melikian A., et al.

EXAMINER INITIAL	OTHER ART – NON PATENT LITERATURE DOCUMENTS (Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.	
	A46	Muller et al., "Involvement of chemokine receptors in breast cancer metastasis," <i>Nature</i> , 410:50-56 (2001).
	A47	Bernhard Neises & Wolfgang Steglich, "Simple Method for the Esterification of Carboxylic Acids ^[1] ," <i>Angew. Chem. Int. Ed. Engl.</i> , 17(7):522-524 (1978).
	A48	Neote et al., "Molecular Cloning, Functional Expression, and Signaling Characteristics of a C-C Chemokine Receptor," <i>Cell</i> , 72:415-425 (1993).
	A49	Oppenheim et al., "Properties of the Novel Proinflammatory Supergene "Interkrine" Cytokine Family ¹ ," <i>Annu. Rev. Immunol.</i> , 9:617-648 (1991).
	A50	Parolin et al., "Use of Murine CXCR-4 as a Second Receptor by Some T-Cell-Tropic Human Immunodeficiency Viruses," <i>J. Virol.</i> , 72(2):1652-1656 (1998).
S62	A51	Ponath et al., "Molecular Cloning and Characterization of a Human Eotaxin Receptor Expressed Selectively on Eosinophils," <i>J. Exp. Med.</i> , 183:2437-2448 (1996).
	A52	Power et al., "Molecular Cloning and Functional Expression of a Novel CC Chemokine Receptor cDNA from a Human Basophilic Cell Line," <i>J. Biol. Chem.</i> , 270(33):19495-19500 (1995).
	A53	Pulaski et al., "Cooperativity of <i>Staphylococcal aureus</i> Enterotoxin B Superantigen, Major Histocompatibility Complex Class II, and CD80 for Immunotherapy of Advanced Spontaneous Metastases in a Clinically Relevant Postoperative Mouse Breast Cancer Model ¹ ," <i>Cancer Research</i> , 60:2710-2715 (2000).
	A54	Thomas J. Schall, "Biology of the Rantes/sis Cytokine Family," <i>Cytokine</i> , 3(3):165-183 (1996).
	A55	Watanabe et al., "The Selective Amination of Carbonyl Compounds Using Iron Pentacarbonyl," <i>Tetrahedron Lett.</i> , No. 22:1879-1880 (1974).
	A56	Wegner et al., "Genomic Organization and Functional Characterization of the Chemokine Receptor CXCR4, a Major Entry Co-receptor for Human Immunodeficiency Virus Type 1," <i>J. Biol. Chem.</i> , 273(8):4754-4760 (1998).
	A57	Yoshida et al., "Identification of Single C Motif-1/Lymphotactin Receptor XCR1," <i>J. Biol. Chem.</i> , 273(26):16551-16554 (1998).

EXAMINER SABIHA GAZI	DATE CONSIDERED 8/25/07
-------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	SERIAL NO. 10/743,281	CASE NO. 10709/63
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE December 22, 2003	GROUP ART UNIT 1616
(use several sheets if necessary)	APPLICANT(S): Anita Melikian et al.	

REFERENCE DESIGNATION	U.S. PATENT DOCUMENTS
1	1,100,000
2	1,100,000
3	1,100,000
4	1,100,000
5	1,100,000
6	1,100,000
7	1,100,000
8	1,100,000
9	1,100,000
10	1,100,000
11	1,100,000
12	1,100,000
13	1,100,000
14	1,100,000
15	1,100,000
16	1,100,000
17	1,100,000
18	1,100,000
19	1,100,000
20	1,100,000
21	1,100,000
22	1,100,000
23	1,100,000
24	1,100,000
25	1,100,000
26	1,100,000
27	1,100,000
28	1,100,000
29	1,100,000
30	1,100,000
31	1,100,000
32	1,100,000
33	1,100,000
34	1,100,000
35	1,100,000
36	1,100,000
37	1,100,000
38	1,100,000
39	1,100,000
40	1,100,000
41	1,100,000
42	1,100,000
43	1,100,000
44	1,100,000
45	1,100,000
46	1,100,000
47	1,100,000
48	1,100,000
49	1,100,000
50	1,100,000
51	1,100,000
52	1,100,000
53	1,100,000
54	1,100,000
55	1,100,000
56	1,100,000
57	1,100,000
58	1,100,000
59	1,100,000
60	1,100,000
61	1,100,000
62	1,100,000
63	1,100,000
64	1,100,000
65	1,100,000
66	1,100,000
67	1,100,000
68	1,100,000
69	1,100,000
70	1,100,000
71	1,100,000
72	1,100,000
73	1,100,000
74	1,100,000
75	1,100,000
76	1,100,000
77	1,100,000
78	1,100,000
79	1,100,000
80	1,100,000
81	1,100,000
82	1,100,000
83	1,100,000
84	1,100,000
85	1,100,000
86	1,100,000
87	1,100,000
88	1,100,000
89	1,100,000
90	1,100,000
91	1,100,000
92	1,100,000
93	1,100,000
94	1,100,000
95	1,100,000
96	1,100,000
97	1,100,000
98	1,100,000
99	1,100,000
100	1,100,000

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES OR NO
SOM	A3	WO 01/98272 A1	06/14/01	PCT		N
	A4	WO 03/007888 A2	07/22/02	PCT		N
	A5	WO 02/24649 A1	09/06/01	PCT		N
	A6	WO 01/55107 A2	01/29/01	PCT		N

**EXAMINER
INITIAL:**

OTHER ART – NON PATENT LITERATURE DOCUMENTS

(Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.

EXAMINER	SABINA GAZ	DATE CONSIDERED	8/25/07
----------	------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.